This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Accofil

Intas Biopharmaceuticals Limited

Drug Names(s): Biosimilar Neupogen, filgrastim, Neukine

Description: Accofil is a biosimilar of Amgen's approved drug, Neupogen (filgrastim).

Filgrastim, like natural G-CSF, stimulates the production of the infection fighting white blood cells called neutrophils.

Deal Structure: Bioton and Intas
In May 2005, SciGen Ltd (a Bioton subsidiary) announces the signing of an exclusive worldwide agreement with ACL Biopharm Ltd, Intas research & development partner, for bulk supply of GCSF (granulocyte colony stimulating factor) and EPO (erythropoietin). The bulk GCSF and EPO will be manufactured by Intas of Ahmedabad, India. SciGen will formulate and package the products in its facility or through a contract manufacturing organization.

As part of the agreement, SciGen is required to pay milestone payments as health registration is secured in major markets from data supplied by Intas. The agreement calls for an option to secure the rights to manufacture the active biopharmaceutical substances through a transfer of technology. Financial terms of the technology transfer are to be mutually agreed. The agreement is for 15 years with an option to renew.

Partners: Bioton S.A.


Accofil News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug